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ABSTRACT 
Implant associated infections are a critical health con-
cern following orthopaedic surgery. Sustained local 
delivery of antibiotics has been suggested as a means 
of preventing these infections. Poly(D,L-lactide) 
(PDLLA) is a biodegradable polymer that has been 
used to coat implants for the delivery of antibiotics 
and other bioactive molecules. While effective, these 
studies show that antibiotics are released in a burst 
profile. Here we evaluated a method for controlled 
release of gentamicin from implant surfaces using the 
palmitate alkyl salt to decrease its solubility in aque-
ous solution. Steel Kirschner wires (K-wires) were 
coated with Gentamicin-palmitate (GP)-PDLLA, 
gentamicin sulphate (GS)-PDLLA or vancomycin 
sulphate (VS)-PDLLA, and elution of antibiotics 
from coated K-wires investigated using HPLC/MS/ 
MS. In contrast to burst antibiotic release from the 
GS-PDLLA and VS-PDLLA groups, GP was released 
in a slower sustained manner. Colonisation and ini-
tial attachment of Staphylococcus aureus Xen29 to 
gentamicin-coated K-wires was reduced by 90% 
when compared to the non-coated control group. 
However there was no statistical difference in recov-
ery of bacteria from GS or GP groups. Bacteria re-
covered from VS-PDLLA coated K-wires decreased 
by 36%. Bioluminescence emitted by S. aureus Xen29 
was also reduced over seven days in the antibiotic 
control groups, demonstrating that growth and 
biofilm development over the longer term was im-
paired by antibiotic-PDLLA coating. These results 
indicate that using alkyl salts of antibiotics may be an 
effective strategy for controlling the release of antibi-
otics from implants. 
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1. INTRODUCTION 
Medical implants and devices are a vital part of modern 
medical practice, including orthopaedics and trauma care, 
with an estimated 600,000 joint prostheses and two mil-
lion fracture fixation devices used each year in the 
United States alone [1]. While improving health out-
comes for patients, implant associated infections have 
become a leading cause of nosocomial infection. Be-
tween 2% of elective orthopaedic surgeries [2], and up to 
44% of individuals with open fractures develop post- 
operative infections [3]. Treatment of these infections 
includes long term antibiotic therapy, possible removal 
of the device and/or debridement of surrounding tissue 
[4,5]. In the most severe cases, amputation may be re-
quired. In addition to the increased health burden, treat-
ment of implant associated infections poses a significant 
economic cost to the health sector [6]. 
Treatment of open fracture associated infections has 
added complications. The initial trauma exposes nor-
mally sterile body sites to the external environment and 
increases the chance of infection. The presence of ne-
crotic anaerobic tissue also promotes infection, and 
damage to vasculature around the wound site can pre-
vent systemically administered antibiotics from reaching 
the site of infection [7]. Osteomyelitis is another signifi-
cant complication associated with open fractures, and 
delivery of antibiotics at concentrations required to kill 
bacteria in the intramedullary cavity is difficult to estab-
lish and maintain. Staphylococcus aureus and coagulase 
negative staphylococci are the major bacterial pathogens 
associated with osteomyelitis [8-11]. 
Current approaches towards reduction of implant re-
lated infection include inhibition of initial bacterial ad-#These two authors contributed equally to this work. 
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hesion, coating implants with polymers which have in-
herent antibacterial activity or by loading of polymers 
with antimicrobial agents [12-16]. Polymer-antibiotic 
coatings are a particularly attractive option for treatment 
of open fractures as these coatings will prevent initial 
bacterial attachment and colonisation of the implant, and 
release of antibiotics from the implant surface may also 
eradicate bacteria from the surrounding tissues. Poly-D, 
L-lactide (PDLLA) is a biodegradable non-toxic poly-
mer that has been used to coat implants with antibiotics 
and other bioactive molecules [17,18]. PDLLA-genta- 
micin sulphate combinations have previously been 
shown to reduce implant colonisation by S. epidermidis 
in in vitro and in vivo models [15]. However, immisci-
bility between the antibiotic salt and the polymer may 
lead to phase separation during coating, with sustained 
release profiles being difficult to achieve. Previous stud-
ies have reported a rapid burst release of gentamicin 
sulphate from the surface of implants in the first hour 
after immersion in PBS [15]. Using poorly water soluble 
salts of antibiotics has been suggested as a method to 
improve miscibility during coating and their temporal 
prophylactic efficiency [19]. In the present study we 
compared the ability of a PDLLA/gentamicin palmitate 
coating to provide sustained release and inhibit S. aureus 
colonisation and biofilm formation on the surface of 
steel Kirschner wires, and compared its performance 
with PDLLA coatings containing gentamicin sulphate 
and vancomycin sulphate. 
2. MATERIALS AND METHODS 
2.1. Bacterial Strains and Media 
Staphylococcus aureus Xen29 is a derivative of the 
biofilm forming S. aureus 12600 that has been recombi-
nantly altered by the introduction of a lux operon de-
rived from Photorhabdus luminescens [20], resulting in 
expression of luciferase. Unless otherwise indicated S. 
aureus Xen29 was grown in Tryptic Soy Broth (TSB), 
Tryptic Soy Agar (TSA) or Columbia agar at 37˚C. The 
minimum inhibitory concentrations (MIC) of gentamicin 
and vancomycin for S. aureus Xen 29 are reported as 
12.5 mg·L–1 and 0.78 mg·L–1 respectively [21]. The MIC 
for gentamicin palmitate was determined to be 25 
mg·L–1. 
2.2. PDLLA-Antibiotic Coating of Kirschner 
Wires 
Three antibiotic-PDLLA combinations, gentamicin sul-
phate (GS), gentamicin palmitate (GP) and vancomycin 
sulphate (VS) were used in this study. The PDLLA used 
(Resomer R203) was a racemic mixture of the D- and 
L-enantiomers of lactic acid with a molecular weight of 
29 kDa. Polymer-antibiotic solutions were prepared with 
the aim of maximising the antibiotic concentration 
whilst simultaneously maintaining solubility of all 
components. Gentamicin sulphate (Sigma-Aldrich AG 
Pty. Ltd., Castle Hill, Australia) was first dissolved in a 
50:50 mixture of dH2O and PEG 1000 (Sigma-Aldrich) 
to improve miscibility with the polymer at a concentra-
tion of 22 mg·ml–1. PDLLA was dissolved in DMSO to 
a final concentration of 62.5 mg·ml–1. The gentamicin 
sulphate solution and PDLLA solutions were mixed in 
a 1:10 ratio with stirring at 50˚C to produce a clear 
solution. The PDDLA-gentamicin palmitate (pentakis 
alkyl salt) solution was prepared in a similar fashion. 
However the GP was first dissolved in chloroform, 
rather than dH2O at a concentration of 29 mg·ml–1. The 
PDDLA-vancomycin solution was prepared by dissolv-
ing vancomycin (22 mg·ml–1) and PDLLA (133.3 
mg·ml–1) in DMSO. Steel Kirschner wires (K-wires, 1.8 
mm diameter) were manufactured by Synthes (Switzer-
land). The K-wires were cut to a length of approxi-
mately 30 mm and dipcoated in 5 ml of coating solution. 
The wire was removed and dried in a vacuum oven for 
24 hr at 50˚C, and then the coating process repeated to 
increase antibiotic content on each K-wire. Each wire 
was inspected visually after coating for completeness of 
the coating. Coated wires were promptly used for all 
experiments. 
2.3. Abrasion Test 
K-wires were cut to 30 mm length and weighed prior to, 
and after coating. The K-wires were then inserted and 
passed through 1.8 mm diameter drill holes in 25 mm 
thick bovine cortical bone specimens and reweighed. 
After gently washing in methanol to remove dislodged 
polymer and bone, the samples were weighed a fourth 
time. The total and percentage loss of coating mass for 
each K-wire was then calculated. 
2.4. Elution Assays 
To determine the rate of release of antibiotics from im-
plant surface, coated K-wires, cut into three 50 mm long 
segments, were placed in 10 ml tubes containing 10 ml 
of PBS (three segments per tube). The samples were 
incubated at 37˚C and 500 µl aliquots collected at 0 h, 
10 min, 1 h, 2 h, 3 h, 4 h, 8 h, 24 h, and 48 h and 7 days. 
Antibiotic concentrations in the samples were deter-
mined by HPLC/MS/MS using an AB/Sciex API4000Q 
(AB/Sciex Concord, Ontario, Canada) mass spectrome-
ter equipped with an electrospray (TurboV) interface 
coupled to a Shimadzu Prominence HPLC system (Shi-
madzu Corp., Kyoto, Japan), resulting in a detection 
limit of 0.5 mg·L–1. 
2.5. Bacterial Attachment Assays 
To measure attachment to K-wires, S. aureus Xen29 was 
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grown overnight in TSB. After washing, the bacteria 
were diluted in PBS to OD595 of 0.1. This suspension 
was further diluted 1:10 in PBS. A 1.3 ml aliquot of this 
suspension, containing approximately 106 CFU of S. 
aureus was then added to 1.5 ml microfuge tubes, and 
individual K-wires added to each tube. After incubation 
at 37˚C for two hours, the K-wires were recovered, 
washed three times in PBS to remove residual antibiotic 
and transiently attached bacteria, and placed in 1.3 ml of 
a 0.5% trypsin/PBS solution at room temperature. Bac-
teria were subsequently dislodged from the surface by 
sonication at 47 KHz for 15 min at room temperature. 
The suspension was then centrifuged to concentrated 
bacteria, and resuspended in PBS. After serial dilution of 
the resuspended samples, aliquots were plated onto TSB. 
The percentage of CFU recovered from PDLLA-antibi- 
otic groups when compared to the average CFU recov-
ered from the uncoated and PDLLA control groups was 
determined for each set of experiments. 
2.6. Inhibition of Biofilm Growth 
Growth of S. aureus Xen29 biofilms on the surface of 
K-wires was monitored for 7 days using an IVIS® 100 
Series (Caliper Life Sciences, Hopkinton, USA) camera 
[20]. Coated and uncoated K-wires were placed in 
6-well tissue culture plate. Five millilitres of TSB con-
taining approximately 105 CFU of S. aureus Xen29 was 
then added to each well, and the plate incubated over-
night without shaking. Next day, the K-wires were re-
covered, gently rinsed, and transferred to a new 6-well 
plate containing fresh TSA. Bioluminescence was cap-
tured using the IVIS camera approximately 20 min after 
transfer to the new 6-well plate. The bioluminescence in 
a defined region surrounding each K-wire was then 
quantified using Living image software. After visualisa-
tion, the K-wires were placed in a new 6-well plate, and 
fresh media (without bacteria) added, and incubation 
continued. 
2.7. Statistical Analysis 
T-tests were used to assess the statistical significance be-
tween mean values of experimental and control groups in 
the study. Differences were considered significant at p ≤ 
0.05. 
3. RESULTS 
3.1. Loading and Mechanical Strength 
The average mass of the GS, GP and VS coating on the 
K-wires was 5.1 mg, 3.2 mg and 3.0 mg respectively. To 
determine the mechanical robustness of the coatings in 
the face of abrasive forces similar to that expected in 
orthopaedic surgery, the K-wires were passed through 
1.8 mm drill holes in bovine cortical bone, and re-
weighed (Figure 1). 
The GS group lost an average 1.9 mg (37% of coating 
mass) per K-wire, whereas the GP group lost an average 
0.5 mg (16%). The difference in total loss and percent-
age loss for the two groups was not statistically signifi-
cant. Very little loss of mass (0.06 mg, 1.5%) was ob-
served in the VS group. 
3.2. Antibiotic Release 
Antibiotics coated to the surface of implants have two 
functions. Firstly, antibiotic on the implant should pre-
vent colonisation by viable bacteria, and subsequent 
biofilm development. Secondly, released antibiotic should 
kill bacteria in the immediate vicinity of the implant. 
The release of antibiotic from the three coating groups 
was investigated by immersing coated K-wires in PBS, 
and measuring concentrations of eluates over time (Fig-
ure 2). For the GS coated K-wires, the majority (71%) 
of the gentamicin was rapidly released in the first 10 min. 
after immersion and reached a maximum concentration 
at 2 hours. The release of vancomycin was even more 
rapid with it reaching 91% of its maximum solution 
concentration within the first 10 min. after immersion. 
Like the GS group, the maximum concentration of van-
comycin in the solution was reached after two hours. In 
contrast to the burst release observed in these two groups, 
the GP group had a much slower rate of release. At 10 
min., the mean concentration of gentamicin in the eluate 
of this group was 6.5 mg·L–1 ± 2.3 mg·L–1, seven fold 
lower than measured in the GS group and 8 fold lower 
than measured in VS group at the same time point. The 
GP group continued to provide a sustained release for up 
to 48hrs and peaked at a concentration of 24 ± 5 mg·L–1, 
2.5 times less than either the GS or VS groups. 
3.3. Inhibition of Colonisation of K-Wires 
To test the ability of antibiotic-PDLLA to inhibit S. 
aureus colonisation, K-wires were incubated in static S. 
aureus suspension, and then washed to remove residual 
antibiotic. Adhered bacteria were then dislodged by  
 
 
Figure 1. Loss of coating mass after abrasion testing. Coated 
K-wires were weighed prior to, and after being passed through 
a 1.8 mm bore hole in bovine cortical bone. Data points repre-
senting individual K-wires prior to and after passing through 
the bone are connected by the lines. 
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sonication, serially diluted and plated onto Columbia 
agar. The total and percentage CFU in the experimental 
group, relative to the CFU recovered from control 
groups (uncoated and PDLLA groups) was then deter-
mined for each individual experiment (Figure 3). Over  
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Figure 2. Elution of antibiotic from gentamicin sulphate () S 
(n = 8), gentamicin palmitate () (n = 5) and vancomycin () 
coated K-wires. K-wires were immersed in PBS, and 500 µl 
aliquots taken over 48 hours. Data is presented as the mean 
concentration of antibiotic in the gentamicin sulphate (n = 8) 
and gentamicin palmitate (n = 5) and vancomycin (n = 8) solu-
tions. Error bars represent the SEM. 
 
 
Figure 3. PDLLA-antibiotic coating inhibit bacterial colonisa-
tion of K-wires. K-wires were incubated with a suspension of S. 
aureus Xen29 for two hours. Bacteria were dislodged from the 
K-wire by incubation with 5% trypsin and sonication. The 
suspensions were serially diluted and plated on agar, incubated 
overnight and CFU determined. Data is presented as the mean 
percentage CFU remaining on each antibiotic-PDLLA group of 
K-wires when compared to the average CFU present on the 
“uncoated” and “PDLLA” coated control K-wires. All experi-
ments were performed at least in triplicate, with at least three 
K-wires represented in each independent experiment. Error 
bars represent SEM. Differences between the mean %CFU of 
control and experimental groups were found to be statistically 
significant. 
all, significantly lower bacterial numbers were recovered 
from the antibiotic coated K-wires. The mean bacterial 
CFU recovered from uncoated and PDLLA coated 
K-wires was 1.2 × 105 ± 5.8 × 104 CFU and 1.0 × 105 ± 
5.8 × 104 CFU respectively. The mean CFU recovery of 
bacteria from the GS (1.1 × 104 ± 6.9 × 103), GP (1.0 × 
103 ± 6.3 × 102) and VS groups (8.1 × 104 ± 4.2 × 104) 
was significantly lower. There was a 93% reduction in 
CFU on GS and 99% reduction of CFU on GP coated 
wires. The 36% reduction in colonisation observed in the 
VS group was not as pronounced but still represents a 
significant decrease in comparison to the control group 
(p < 0.05). 
3.4. Inhibition of Biofilm Formation 
The results of the colonisation studies demonstrated that 
all the antibiotic coatings inhibited initial colonisation 
events. To assess whether the reduced colonisation had 
any impact on biofilm formation, we next incubated K- 
wires with recombinant S. aureus Xen29 over a period 
of seven days, and captured bioluminescence emitted by 
the bacteria using an IVIS CCD camera (Figure 4). The 
advantage of the IVIS system over other methods for 
bacterial monitoring lies in the ability to measure the 
same sample at multiple time points. For the uncoated 
group, an initial signal intensity of 3.1 × 104 photon/s 
was recorded on day 1. The luminescence then increased 
to a maximum on the fourth day of the incubation, and 
declined slowly after this time point. In contrast to other 
groups, the photonic signal observed on day 1 for the 
PDLLA control group exceeded 105 photons/s. The rela-
tively higher level of colonisation, as measured by lu-
minescence, was maintained throughout the experiment. 
After this time point, biofilm growth continued to in-
crease over the course of the experiment. For the antibi- 
 
 
Figure 4. Biofilm formation on the surface of K-wires. K- 
wires were incubated with S. aureus Xen29 overnight and bio-
luminescence emitted by the bacteria monitored daily using an 
IVIS CCD camera. Figure shows mean luminescent signal 
intensity of control and experimental groups measured over the 
seven days of the experiment. 
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otic-PDLLA groups, the signal intensity observed on the 
first day was similar to the uncoated sample. 
For the GS group, signal intensity rose to a maximum 
of 6.5 × 104 photon/s on day 6. However this was not 
significantly greater than the intensity on day 1. Simi-
larly, no statistical increase in the intensity of signal in 
the vancomycin group was observed. The GP group also 
showed no increase in intensity over the first four days. 
While a small increase was observed in the last two days 
of the experiment, the signal intensity was still ten times 
lower than the PDDLA group on comparable days. Us-
ing the IVIS camera, we were also able to detect bacteria 
in the culture supernatant for each sample for each day 
of the experiment (data not shown). Taken together these 
results indicated that the three antibiotic groups were 
effective at reducing biofilm formation on the K-wires. 
4. DISCUSSION 
Infections are still among the leading causes for compli-
cations in orthopaedic surgery, ranging in frequency 
from 1% - 5% in elective, joint replacement surgery, to 
higher rates in osteosynthesis of open fractures [9]. They 
are painful, difficult to treat and can lead to implant- 
related osteomyelitis. Furthermore, these complications 
cause prolonged hospitalisation and are associated with 
significantly increased costs. Therefore, antibiotic pro-
phylaxis, usually via intravenous administration, is a 
routine procedure in these surgeries [22]. Although this 
systemic prophylaxis is successful in most cases, deliv-
ery to wounds can be problematic due to the presence of 
ischemic tissue. The difficulty in delivering antibiotics to 
these tissues also increases the risk of the growth of im-
plant associated biofilms, which show high resistance to 
antibiotics and the immune system and often require 
implant removal [23,24]. 
The development of biodegradable implant coating 
techniques that provide both local delivery of antibiotics 
and prevent biofilm formation is an attractive approach 
for the prevention of these infections. Local delivery 
ensures that high concentrations of antibiotic are deliv-
ered at the wound site where infections are most likely to 
occur, whilst antibiotics on the surface of the implant 
may prevent bacterial colonisation. Antibiotic release 
from these coatings occurs in a burst release fashion, 
which is desirable in some clinical situations (e.g. open 
fractures with contamination), but which on its own may 
not be ideal to prevent infections caused by delayed or 
repeated exposure to bacteria. To that end we investi-
gated the use of an alkyl salt of gentamicin, gentamicin 
palmitate, to limit burst release and extend delivery time 
from PDLLA coated implants. 
Antibiotic miscibility with the coating solution had a 
large effect on the film toughness. Increasing the misci-
bility of the antibiotic with PDLLA resulted in tougher 
films with the gentamicin palmitate/PDLLA film as evi-
dent by its losing less mass when compared to the gen-
tamicin sulphate/PDLLA film (although the difference 
was not statistically significant). Vancomycin, which 
was miscible in all proportions with PDLLA, lost very 
little mass under our test conditions. We attribute the 
difference in mass loss to the disruption that immiscible 
particles, such as gentamicin sulphate, cause to the film 
structure upon drying. It is well known that the interface 
between immiscible particles and polymer films has a 
great influence on the toughness of the films [25,26]. 
Particles with no adhesive interaction with the polymer 
essentially act as porogens, creating defects in the film. 
Conversely, the miscibility of vancomycin provided a 
more even distribution and no reduction in film tough-
ness. Whilst not specifically reported here, it was possi-
ble to include too much vancomycin in the films with 
concentrations over 50 mg·ml–1 completely disrupting 
stable film formation. These coatings were shed from the 
implant surface (data not shown). 
The release rates of the gentamicin and vancomycin in 
our study are similar to those reported when no coating 
was used on implants [27]. Under our time frame the 
polymer did not degrade significantly or show any effect 
of controlling the release as has been reported by other 
authors [28]. We attribute this difference to our coating 
procedure. Our procedure produced very smooth films 
unlike those prepared by Aviv et al. whose coating pro-
cedure produced slightly porous films with phase sepa-
rated domains of antibiotic. In their system early pro-
longed release is most likely due to an increased path 
length of antibiotic through pores in the polymer surface, 
not degradation mediated release as they saw at later 
time points. It is likely that our procedure of improving 
the solution miscibility of the antibiotics with the poly-
mer and the smoothness of the films that were created 
reduced the porosity and effectively trapped any non- 
surface bound antibiotic in the polymer. Our release re-
sults, coupled with the long degradation time of PDLLA 
[29,30], suggest that the release of these antibiotics over 
the time frame considered is mostly due to residual anti-
biotic on the surface. We demonstrated that the use of 
gentamicin palmitate does result in an extended delivery 
compared to both gentamicin sulphate and vancomycin, 
but in less total antibiotic release. We would expect that 
the longer release to be due to a decreased solubility of 
the palmitate salt in PBS. Similar to gentamicin sulphate 
and vancomycin, this would be surface adsorbed gen-
tamicin palmitate that slowly dissolves in PBS. There 
are two possible explanations for a lower total amount of 
gentamicin palmitate released. As the salt is sparingly 
soluble in PBS it may be that the solubility limit was 
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reached in the volume of PBS used in the elution ex-
periment. Whilst we cannot totally rule this explanation 
out, we believe that the low total amount released (24 
mg·L–1) is well below the solubility limit of the antibi-
otic in PBS. The media being changed constantly in the 
biofilm experiments and the increase in bacteria at four 
days also suggests that the elution experiments closely 
reflect the amount of antibiotic able to be released. A 
more likely explanation is that our coating procedure 
results in less total antibiotic adsorbed to the surface. 
Care was taken to ensure that similar molar concentra-
tions of gentamicin were present in both the sulphate and 
palmitate coating solutions and that the coating proce-
dures were as similar as possible. However the differing 
solvents used, i.e. H20/PEG1000/DMSO combination for 
the gentamicin sulphate and just chloroform for the gen-
tamicin palmitate likely resulted in differing levels of 
partitioning of the antibiotic to the surface during the 
coating procedure. It should be possible to increase the 
amount of gentamicin palmitate on the surface simply by 
increasing the coating solution concentration or increas-
ing the number of dip coatings. This would certainly 
increase the total amount of antibiotic released and may 
possibly extend the delivery time. The slower sustained 
release of antibiotic may be particularly effective in 
combating late onset osteomyelitis [31]. 
Despite having different delivery profiles all three an-
tibiotics reduced the numbers of attached bacteria. Both 
salts of gentamicin were equally effective in reducing 
bacterial attachment and were in fact better than vanco-
mycin at the two hour time point used for testing. Given 
that all antibiotics were present in concentrations above 
their minimum inhibitory concentrations this difference 
may be due to vancomycin’s slow bactericidal activity 
compared with gentamicin [32]. The longer incubation 
times in the biofilm assays, and similar reduction in 
bacterial load on gentamicin and vancomycin-coated 
K-wires would seem to support this. Unlike the results of 
Gollwitzer et al. [13] we did not see a reduction in the 
attachment of viable bacteria on PDLLA-coated steel 
when compared to uncoated steel. The contradicting 
results may be due to the different bacterial species used, 
(S. aureus vs S. epidermidis) although PDLLA coated 
wires have shown no inhibitory effect on bacterial 
growth in vivo [33]. 
Under the conditions used in the study, the presence 
of antibiotics on the K-wires was able to reduce biofilm 
formation for at least seven days, as determined through 
measurement of bioluminescence. Although vancomycin 
was less effective in preventing initial colonisation, it is 
as effective as the gentamicin salts in retarding biofilm 
formation compared with both the uncoated and PDLLA 
coated wires. Our results also showed that an increase in 
bacterial load after day 4 occurred for K-wires coated 
with gentamicin palmitate, but not gentamicin sulphate. 
This suggests that some viable S. aureus, below the de-
tection limits of the assay, remained on the GP coated 
K-wires on days 1 - 4. The sustained elution profile of 
the GP group, resulting in reduced concentrations of 
gentamicin at specific time-points, may have enabled 
small numbers of bacteria to survive. The subsequent 
increase in bacterial numbers after four days suggests 
that the majority of gentamicin had been released by this 
time, allowing the growth of S. aureus. This contrasts 
with the high concentrations of gentamicin in solution 
associated with the burst kinetics of the gentamicin sul-
phate group, possibly killing all bacteria in the assay at 
an early time-point. These observations highlight the 
importance of achieving the appropriate antibiotic elu-
tion kinetics in the clinical environment. While it is de-
sirable for antibiotic to elute from implants in appropri-
ate concentrations to kill surrounding bacteria, sufficient 
antibiotic must also remain attached to the implants to 
help prevent later colonisation events. One of the draw-
backs of this protocol is that we did not challenge the 
coated rods after the burst release was complete, as 
might be expected in vivo. 
Collectively these results show that the presence of 
antibiotics on implants can reduce bacterial attachment 
and biofilm formation and that antibiotic/polymer misci-
bility affects the coating toughness, but not the delivery 
profile. We have demonstrated that gentamicin-palmitate 
has a reduced rate of release from metal surgical im-
plants, but that this did not translate to a significant re-
duction in bacterial attachment and biofilm formation in 
our model. Ultimately, the effect of different release 
profiles on the prevention of implant-related bone infec-
tions will have to be tested and demonstrated in suitable 
pre-clinical in vivo animal models. Nevertheless the sus-
tained release kinetics of gentamicin palmitate from 
PDLLA, as demonstrated in our in vitro experiments, may 
represent a strategy for improving the release of antibiot-
ics from polymer coatings for combating infection. 
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